CCR1 antagonists: What have we learned from clinical trials

Current Topics in Medicinal Chemistry

Volumn 10, Issue 13, 2010, Pages 1268-1277

  Gladue, Ronald P ^a   Brown, Matthew F ^a   Zwillich, Samuel H ^a  

^a PFIZER INC   (United States)

Author keywords

715; AZD 4818; BX471; CCL3; CCL5; CCR1; CP 481; MLN 3897; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; AZD 4818; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CP 481715; MLN 3897; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; HUMANS; LIGANDS; MOLECULAR CONFORMATION; RECEPTORS, CCR1; STEREOISOMERISM;

EID: 77955631528     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791561237     Document Type: Article

References (73)

1. Neote, K.; DiGregorio, D.; Mak, J. Y.; Horuk, R.; Schall, T. J. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell, 1993, 72(3), 415-425.
2. Zlotnik, A.; Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12(2), 121-7.
3. Tsou, C. L.; Gladue, R. P.; Carroll, L. A.; Paradis, T.; Boyd, J. G.; Nelson, R. T.; Neote, K.; Charo, I. F. Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J. Exp. Med., 1998, 188(3), 603-8.
4. Gladue, R. P.; Tylaska, L. A.; Brissette, W. H.; Lira, P. D.; Kath, J. C.; Poss, C. S.; Brown, M. F.; Paradis, T. J.; Conklyn, M. J.; Og-borne, K. T.; McGlynn, M. A.; Lillie, B. M.; DiRico, A. P.; Mairs, E. N.; McElroy, E. B.; Martin, W. H.; Stock, I. A.; Shepard, R. M.; Showell, H. J.; Neote, K. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem., 2003, 278(42), 40473-40480.
5. Ward, S. G.; Bacon, K.; Westwick, J. Chemokines and T lymphocytes: more than an attraction. Immunity, 1998, 9(1), 1-11.
6. Gao, J. L.; Wynn, T. A.; Chang, Y.; Lee, E. J.; Broxmeyer, H. E.; Cooper, S.; Tiffany, H. L.; Westphal, H.; Kwon-Chung, J.; Murphy, P. M. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med., 1997, 185(11), 1959-68.
7. Colantonio, L.; Iellem, A.; Clissi, B.; Pardi, R.; Rogge, L.; Siniga-glia, F.; D'Ambrosio, D. Upregulation of integrin alpha6/beta1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood, 1999, 94 (9), 2981-2989.
8. Fahey, T. J. 3rd; Tracey, K. J.; Tekamp-Olson, P.; Cousens, L. S.; Jones, W. G.; Shires, G. T.; Cerami, A.; Sherry, B. Macrophage inflammatory protein 1 modulates macrophage function. J. Immunol., 1992, 148(9), 2764-2769.
9. Klier, C. M.; Nelson, E. L.; Cohen, C. D.; Horuk, R.; Schlondorff, D.; Nelson, P. J. Chemokine-Induced secretion of gelatinase B in primary human monocytes. Biol. Chem., 2001, 382(9), 1405-1410.
10. Robinson, S. C.; Scott, K. A.; Balkwill, F. R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur. J. Immunol., 2002, 32, (2), 404-12.
11. Varani, S.; Frascaroli, G.; Homman-Loudiyi, M.; Feld, S.; Landini, M. P.; Soderberg-Naucler, C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J. Leukoc. Biol., 2005, 77(2), 219-228.
12. Cheng, S. S.; Lai, J. J.; Lukacs, N. W.; Kunkel, S. L. Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils. J. Immunol., 2001, 166(2), 1178-1184.
13. Lee, S. C.; Brummet, M. E.; Shahabuddin, S.; Woodworth, T. G.; Georas, S. N.; Leiferman, K. M.; Gilman, S. C.; Stellato, C.; Gladue, R. P.; Schleimer, R. P.; Beck, L. A. Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. J. Immunol., 2000, 164(6), 3392-3401.
14. Broxmeyer, H. E.; Cooper, S.; Hangoc, G.; Gao, J. L.; Murphy, P. M. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J. Exp. Med., 1999, 189(12), 1987-1992.
15. Tanabe, S.; Heesen, M.; Berman, M. A.; Fischer, M. B.; Yoshi-zawa, I.; Luo, Y.; Dorf, M. E. Murine astrocytes express a functional chemokine receptor. J. Neurosci., 1997, 17(17), 6522-6528.
16. Joubert, P.; Lajoie-Kadoch, S.; Welman, M.; Dragon, S.; Letuvee, S.; Tolloczko, B.; Halayko, A. J.; Gounni, A. S.; Maghni, K.; Hamid, Q. Expression and regulation of CCR1 by airway smooth muscle cells in asthma. J. Immunol., 2008, 180(2), 1268-1275.
17. Halks-Miller, M.; Schroeder, M. L.; Haroutunian, V.; Moenning, U.; Rossi, M.; Achim, C.; Purohit, D.; Mahmoudi, M.; Horuk, R. CCR1 is an early and specific marker of Alzheimer's disease. Ann. Neurol., 2003, 54(5), 638-646.
18. Lean, J. M.; Murphy, C.; Fuller, K.; Chambers, T. J. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J. Cell Biochem., 2002, 87(4), 386-393.
19. Gladue, R. P.; Cole, S. H.; Roach, M. L.; Tylaska, L. A.; Nelson, R. T.; Shepard, R. M.; McNeish, J. D.; Ogborne, K. T.; Neote, K. S. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J. Immunol., 2006, 176(5), 3141-3148.
20. rd ed.; Hunder, G. G. Ed. Lippincott Williams and Wil-kins: Philadelphia, 2002; pp. 1-48.
21. Jenkins, J. K.; Hardy, K. J.; McMurray, R. W. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am. J. Med. Sci., 2002, 323(4), 171-180.
22. Tak, P. P.; Smeets, T. J.; Daha, M. R.; Kluin, P. M.; Meijers, K. A.; Brand, R.; Meinders, A. E.; Breedveld, F. C. Analysis of the syno-vial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum., 1997, 40(2), 217-225.
23. al-Mughales, J.; Blyth, T. H.; Hunter, J. A.; Wilkinson, P. C. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin. Exp. Immunol., 1996, 706(2), 230-236.
24. Ellingsen, T.; Buus, A.; Moller, B. K.; Stengaard-Pedersen, K. In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters. Scand J. Rheumatol., 2000, 29(4), 216-221.
25. Katrib, A.; Tak, P. P.; Bertouch, J. V.; Cuello, C.; McNeil, H. P.; Smeets, T. J.; Kraan, M. C.; Youssef, P. P. Expression of chemoki-nes and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology, (Oxford) 2001, 40(9), 988-994.
26. Koch, A. E.; Kunkel, S. L.; Harlow, L. A.; Mazarakis, D. D.; Haines, G. K.; Burdick, M. D.; Pope, R. M.; Strieter, R. M. Macro-phage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J. Clin. Invest, 1994, 93(3), 921-928.
27. Robinson, E.; Keystone, E. C.; Schall, T. J.; Gillett, N.; Fish, E. N. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin. Exp. Immunol., 1995, 707(3), 398-407.
28. Volin, M. V.; Shah, M. R.; Tokuhira, M.; Haines, G. K.; Woods, J. M.; Koch, A. E. RANTES expression and contribution to mono-cyte chemotaxis in arthritis. Clin. Immunol. Immunopathol., 1998, 89(1), 44-53.
29. Koch, A. E.; Kunkel, S. L.; Strieter, R. M. Cytokines in rheumatoid arthritis. J. Investig. Med., 1995, 43(1), 28-38.
30. Brennan, F. M.; Maini, R. N.; Feldmann, M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol., 1998, 20(1-2), 133-147.
31. Plater-Zyberk, C.; Hoogewerf, A. J.; Proudfoot, A. E.; Power, C. A.; Wells, T. N. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett., 1997, 57(1-3), 117-120.
32. Kasama, T.; Strieter, R. M.; Lukacs, N. W.; Lincoln, P. M.; Burdick, M. D.; Kunkel, S. L. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J. Clin. Invest., 1995, 95(6), 2868-2876.
33. Barnes, D. A.; Tse, J.; Kaufhold, M.; Owen, M.; Hesselgesser, J.; Strieter, R.; Horuk, R.; Perez, H. D. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest., 1998, 707(12), 2910-2919.
34. Sorensen, T. L.; Ransohoff, R. M. Etiology and pathogenesis of multiple sclerosis. Semin. Neurol., 1998, 78(3), 287-294.
35. Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P.; Libonati, M. A.; Willmer-Hulme, A. J.; Dalton, C. M.; Miszkiel, K. A.; O'Connor, P. W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2003, 348(1), 1523.
36. Misu, T.; Onodera, H.; Fujihara, K.; Matsushima, K.; Yoshie, O.; Okita, N.; Takase, S.; Itoyama, Y. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J. Neuroimmunol., 2001, 114(1-2), 207-12.
37. Balashov, K. E.; Rottman, J. B.; Weiner, H. L.; Hancock, W. W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyeli-nating brain lesions. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6873-6878.
38. Baranzini, S. E.; Elfstrom, C.; Chang, S. Y.; Butunoi, C.; Murray, R.; Higuchi, R.; Oksenberg, J. R. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol., 2000, 765(11), 6576-6582.
39. Sorensen, T. L.; Tani, M.; Jensen, J.; Pierce, V.; Lucchinetti, C.; Folcik, V. A.; Qin, S.; Rottman, J.; Sellebjerg, F.; Strieter, R. M.; Frederiksen, J. L.; Ransohoff, R. M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest., 1999, 703(6), 807-815.
40. Karpus, W. J.; Kennedy, K. J. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol., 1997, 62(5), 681-687.
41. Youssef, S.; Wildbaum, G.; Karin, N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J. Autoimmun., 1999, 73(1), 21-29.
42. Rottman, J. B.; Slavin, A. J.; Silva, R.; Weiner, H. L.; Gerard, C. G.; Hancock, W. W. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur. J. Immunol., 2000, 30(8), 2372-7.
43. Ng, H. P.; May, K.; Bauman, J. G.; Ghannam, A.; Islam, I.; Liang, M.; Horuk, R.; Hesselgesser, J.; Snider, R. M.; Perez, H. D.; Mor-rissey, M. M. Discovery of novel non-peptide CCR1 receptor antagonists. J. Med. Chem., 1999, 42(22), 4680-4694.
44. Merritt, J. R.; Liu, J.; Quadros, E.; Morris, M. L.; Liu, R.; Zhang, R.; Jacob, B.; Postelnek, J.; Hicks, C. M.; Chen, W.; Kimble, E. F.; Rogers, W. L.; O'Brien, L.; White, N.; Desai, H.; Bansal, S.; King, G.; Ohlmeyer, M. J.; Appell, K. C.; Webb, M. L. Novel Pyrrolidine Ureas as C-C Chemokine Receptor 1 (CCR1) Antagonists. J. Med. Chem., 2009. Epub ahead of print.
45. Vergunst, C. E.; Gerlag, D. M.; von Moltke, L.; Karol, M.; Wyant, T.; Chi, X.; Matzkin, E.; Leach, T.; Tak, P. P. MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum., 2009, 60(12), 3572-3581.
46. Ainge, D. B. J.; Pedge, N.; Sinclair, R.; Sleigh, C.; Stefinovic, M.; Vaz, L-M.; Way, E. Development of a multikilogram synthesis of a chiral epoxide precursor to a CCR1 antagonist. Use of in situ monitoring for informed optimization via fragile intermediates. Org. Process Res. Dev., 2009, in press.
47. Cheng, J. F.; Jack, R. CCR1 antagonists. Mol. Divers, 2008, 72(1), 17-23.
48. Norman, P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opin. Ther. Pat., 2009, 79(11), 1629-1633.
49. Gladue, R. P.; Zwillich, S. H.; Clucas, A. T.; Brown, M. F. CCR1 antagonists for the treatment of autoimmune diseases. Curr. Opin. Invest. Drugs, 2004, 5(5), 499-504.
50. Elices, M. J. BX-471 Berlex. Cur. Opin Investig Drugs, 2002, 3(6), 865-869.
51. Brown, M. F.; Avery, M.; Brissette, W. H.; Chang, J. H.; Colizza, K.; Conklyn, M.; DiRico, A. P.; Gladue, R. P.; Kath, J. C.; Krueger, S. S.; Lira, P. D.; Lillie, B. M.; Lundquist, G. D.; Mairs, E. N.; McElroy, E. B.; McGlynn, M. A.; Paradis, T. J.; Poss, C. S.; Rossulek, M. I.; Shepard, R. M.; Sims, J.; Strelevitz, T. J.; Trues-dell, S.; Tylaska, L. A.; Yoon, K.; Zheng, D. Novel CCR1 antagonists with improved metabolic stability. Bioorg. Med. Chem. Lett., 2004, 14(9), 2175-2179.
52. Kath, J. C.; Brissette, W. H.; Brown, M. F.; Conklyn, M.; DiRico, A. P.; Dorff, P.; Gladue, R. P.; Lillie, B. M.; Lira, P. D.; Mairs, E. N.; Martin, W. H.; McElroy, E. B.; McGlynn, M. A.; Paradis, T. J.; Poss, C. S.; Stock, I. A.; Tylaska, L. A.; Zheng, D. Potent small molecule CCR1 antagonists. Bioorg. Med. Chem. Lett., 2004, 14(9), 2169-2173.
53. Kath, J. C.; DiRico, A. P.; Gladue, R. P.; Martin, W. H.; McElroy, E. B.; Stock, I. A.; Tylaska, L. A.; Zheng, D. The discovery of structurally novel CCR1 antagonists derived from a hydroxyethyl-ene peptide isostere template. Bioorg. Med. Chem. Lett., 2004, 14(9), 2163-2167.
54. Clucas, A. T.; Shah, A.; Zhang, Y. D.; Chow, V. F.; Gladue, R. P. Phase I evaluation of the safety, pharmacokinetics and pharma-codynamics of CP-481,715. Clin. Pharmacokinet., 2007, 46(9), 757-766.
55. Haringman, J. J.; Kraan, M. C.; Smeets, T. J.; Zwinderman, K. H.; Tak, P. P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62(8), 715-721.
56. Felson, D. T.; Anderson, J. J.; Boers, M.; Bombardier, C.; Furst, D.; Goldsmith, C.; Katz, L. M.; Lightfoot, R. Jr.; Paulus, H.; Strand, V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum., 1995, 38(6), 727-735.
57. Liang, M.; Mallari, C.; Rosser, M.; Ng, H. P.; May, K.; Monahan, S.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Shaw, K.; Wei, G. P.; Xu, W.; Zhao, Z.; Ho, E.; Shen, J.; Oanh, H.; Subra-manyam, B.; Vergona, R.; Taub, D.; Dunning, L.; Harvey, S.; Snider, R. M.; Hesselgesser, J.; Morrissey, M. M.; Perez, H. D. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem., 2000, 275(25), 19000-19008.
58. Horuk, R.; Clayberger, C.; Krensky, A. M.; Wang, Z.; Grone, H. J.; Weber, C.; Weber, K. S.; Nelson, P. J.; May, K.; Rosser, M.; Dunning, L.; Liang, M.; Buckman, B.; Ghannam, A.; Ng, H. P.; Islam, I.; Bauman, J. G.; Wei, G. P.; Monahan, S.; Xu, W.; Snider, R. M.; Morrissey, M. M.; Hesselgesser, J.; Perez, H. D. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem., 2001, 276(6), 4199-4204.
59. Horuk, R.; Shurey, S.; Ng, H. P.; May, K.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Wei, G. P.; Xu, W.; Liang, M.; Rosser, M.; Dunning, L.; Hesselgesser, J.; Snider, R. M.; Morris-sey, M. M.; Perez, H. D.; Green, C. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett., 2001, 76(3), 193-201.
60. Anders, H. J.; Vielhauer, V.; Frink, M.; Linde, Y.; Cohen, C. D.; Blattner, S. M.; Kretzler, M.; Strutz, F.; Mack, M.; Grone, H. J.; Onuffer, J.; Horuk, R.; Nelson, P. J.; Schlondorff, D. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest., 2002, 709(2), 251-259.
61. Zipp, F.; Hartung, H. P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stan-gel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology, 2006, 67(10), 1880-3.
62. Feldmann, M.; Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol, 2001, 19, 163-196.
63. Tylaska, L. A.; Boring, L.; Weng, W.; Aiello, R.; Charo, I. F.; Rollins, B. J.; Gladue, R. P. Ccr2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine, 2002, 18(4), 184-190.
64. Cardona, A. E.; Sasse, M. E.; Liu, L.; Cardona, S. M.; Mizutani, M.; Savarin, C.; Hu, T.; Ransohoff, R. M. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood, 2008, 112(2), 256-263.
65. Richardson, R. M.; Pridgen, B. C.; Haribabu, B.; Snyderman, R. Regulation of the human chemokine receptor CCR1. Cross-regulation by CXCR1 and CXCR2. J. Biol. Chem., 2000, 275(13), 9201-9208.
66. Pattison, J.; Nelson, P. J.; Huie, P.; von Leuttichau, I.; Farshid, G.; Sibley, R. K.; Krensky, A. M. RANTES chemokine expression in cell-mediated transplant rejection of the kidney.[comment]. Lancet, 1994, 343(8891), 209-211.
67. Gao, W.; Topham, P. S.; King, J. A.; Smiley, S. T.; Csizmadia, V.; Lu, B.; Gerard, C. J.; Hancock, W. W. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest., 2000, 105 (1), 35-44.
68. Miller, A. L.; Gerard, C.; Schaller, M.; Gruber, A. D.; Humbles, A. A.; Lukacs, N. W. Deletion of CCR1 attenuates pathophysiologic responses during respiratory syncytial virus infection. J. Immunol., 2006, 176(4), 2562-2567.
69. He, M.; Horuk, R.; Moochhala, S. M.; Bhatia, M. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292(4), G1173-1180.
70. Uneda, S.; Hata, H.; Matsuno, F.; Harada, N.; Mitsuya, Y.; Ka-wano, F.; Mitsuya, H. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br. J. He-matol., 2003, 120(1), 53-55.
71. Vallet, S.; Raje, N.; Ishitsuka, K.; Hideshima, T.; Podar, K.; Chhetri, S.; Pozzi, S.; Breitkreutz, I.; Kiziltepe, T.; Yasui, H.; Ocio, E. M.; Shiraishi, N.; Jin, J.; Okawa, Y.; Ikeda, H.; Mukherjee, S.; Vaghela, N.; Cirstea, D.; Ladetto, M.; Boccadoro, M.; Anderson, K. C. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogene-sis and inhibits the interaction of multiple myeloma cells and os-teoclasts. Blood, 2007, 110(10), 3744-3752.
72. Abe, M.; Hiura, K.; Wilde, J.; Moriyama, K.; Hashimoto, T.; Ozaki, S.; Wakatsuki, S.; Kosaka, M.; Kido, S.; Inoue, D.; Matsu-moto, T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood, 2002, 100(6), 2195-2202.
73. Carson, K.G. H. G. CCR1 antagonists for the treatment of demye-linating inflammatory disease. Patent WO 2004/043965, 2004.